Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Short Interest Falls 39.5%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 7,784 shares, a decrease of 39.5% from the September 30th total of 12,856 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 11,229 shares, the days-to-cover ratio is currently 0.7 days.

Invesco Biotechnology & Genome ETF Stock Down 0.9%

Shares of PBE stock opened at $102.50 on Friday. The firm has a 50 day moving average price of $96.99 and a two-hundred day moving average price of $87.26. The company has a market capitalization of $445.88 million, a PE ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a 12-month low of $73.16 and a 12-month high of $104.24.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

Large investors have recently made changes to their positions in the company. Outlook Wealth Advisors LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth $1,468,000. Oakworth Capital Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $59,000. Penobscot Investment Management Company Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $1,892,000. Sowell Financial Services LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $298,000. Finally, Investment House LLC acquired a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $582,000.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.